<DOC>
	<DOCNO>NCT02260037</DOCNO>
	<brief_summary>Safety , tolerability pharmacokinetics</brief_summary>
	<brief_title>Dose Tolerance Study Healthy Male Volunteers After Intranasal Application Epinastine Nasal</brief_title>
	<detailed_description />
	<mesh_term>Epinastine</mesh_term>
	<criteria>All participant study healthy , range 21 50 year age within ± 20 % normal weight ( Broca Index ) Subsequently subject medical history take receive complete medical examination ( incl . blood pressure pulse rate measurement ) well 12lead ECG . Haematological , hepatic renal function test carry laboratory ( Bioscientia Ingelheim , Germany ) . The subject fast 12 hour collection specimens laboratory evaluation . The mentioned examination perform within 14 day first administration test substance In accordance good clinical practice ( GCP ) local legislation volunteer give write informed consent prior admission study Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month less ten halflives respective drug enrolment study Use drug might influence result trial ( ≤ one week prior administration trial ) Participation another trial investigational drug ( ≤ two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( ≥ 100 mL within four week prior administration trial ) Excessive physical activity ( within last week study ) Any laboratory value outside reference range clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>